CFTR

Across TCGA pan-cancer cohorts, CFTR Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated CFTR data layer compared with 23 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher CFTR Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CFTR expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

LIHC, LUSC, and SARC are the cancer types where CFTR Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	III,IV	0.093	0.649	<.001	18	view →
LUSC	OS	Median	III,IV	0.108	0.691	<.001	18	view →
SARC	DFS	Median	All	0.129	0.613	.002	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
STAD	OS	Median	II,III,IV	0.061	0.711	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
ACC	OS	Median	All	0.149	0.686	.047	3	view →
BLCA	OS	Median	II,III,IV	0.886	0.595	.046	2	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

CFTR–LIHC (OS)

Open the LIHC breakdown →